Evidence map›Paper›PMID 35128403›Full record

ArticleBMJ neurology open2022

Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.

Marta F Pereira, Tim Buchanan, Günter U Höglinger, Marko Bogdanovic, George Tofaris, Simon Prangnell, Nagaraja Sarangmat, James J FitzGerald, Chrystalina A Antoniades

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ neurology open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  10. Disease modification in Parkinsonism: obstacles and ways forward.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marta F PereiraNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Tim BuchananUCB Biopharma S.R.L, Brussels, UK.
Günter U HöglingerDepartment of Neurology, Technische Universität München & Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Munich, Germany.ORCID 0000-0001-7587-6187
Marko BogdanovicDepartment of Neurology, Oxford University Hospitals, Oxford, UK.
George TofarisNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Simon PrangnellNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Nagaraja SarangmatDepartment of Neurology, Oxford University Hospitals, Oxford, UK.
James J FitzGeraldNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Chrystalina A AntoniadesNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0002-1192-3834
University of Oxford · GBOxford University Hospitals NHS Trust · GBGerman Center for Neurodegenerative Diseases · DE

Funding

Medical Research Council MR/V007068/1
6 · The paper itself

Abstract

backgroundProgressive supranuclear palsy (PSP) is a rare neurodegenerative condition characterised by a range of motor and cognitive symptoms. Very little is known about the longitudinal change in these symptoms over time. Moreover, the effectiveness of clinical scales to detect early changes in PSP is still a matter of debate.

objectiveWe aimed to determine longitudinal changes in PSP features using multiple closely spaced follow-up time points over a period of 2 years.

resultsThe Montreal Cognitive Assessment, but not the Mini-Mental State Examination, detected cognitive decline at baseline. Both scales revealed poor longitudinal sensitivity to clinical change in global cognitive symptoms. Conversely, the Movement Disorders Society Unified Parkinson's disease Rating Scale - part III and the PSP Rating Scale (PSPRS) reliably detected motor decline less than 2 years after disease onset. The 'Gait/Midline' PSPRS subscore consistently declined over time, with the earliest change being observed 6 months after baseline assessment.

conclusionWhile better cognitive screening tools are still needed to monitor cognitive decline in PSP, motor decline is consistently captured by clinical rating scales. These results support the inclusion of multiple follow-up time points in longitudinal studies in the early stages of PSP.

Indexed as

clinical neurologymotor control

Identifiers

PMID35128403
PMCPMC8785161
OpenAlexW4206998634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.